130 results
Page 5 of 7
6-K
EX-99.1
t1bu87
6 Apr 21
VBL Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
3:33pm
6-K
EX-99.3
q60sarcqvadox68hpd0j
15 Jan 21
Ordinary Share Purchase Agreement
7:01am
424B5
o9b97xuv
15 Jan 21
Prospectus supplement for primary offering
7:00am
424B3
sef9oq2f
16 Nov 20
Prospectus supplement
7:15am
6-K
stwrmqm92 4ae1u9mmxf
16 Nov 20
Current report (foreign)
7:00am
6-K
EX-99.1
uusgb3brry9jg1agmh
13 Oct 20
VBL Therapeutics Announces Appointment of Marc Kozin as Vice Chairman of Board of Directors
8:30am
424B3
5x0cj8xqi7fiikpl0 s8
26 Aug 20
Prospectus supplement
5:21pm
6-K
bswql
13 Aug 20
Current report (foreign)
7:00am
6-K
EX-99.1
puw53qj3icuhb05
12 Aug 20
Current report (foreign)
8:45am
6-K
EX-99.2
7w7g3m 4msgqcu7oimin
28 May 20
Notice of Annual General Meeting of Shareholders
9:14am
6-K
h18la9swz3tkm
14 May 20
Current report (foreign)
7:25am
6-K
EX-10.1
ke0tyg prz5e5hriz09g
12 May 20
Current report (foreign)
12:04pm
6-K
EX-99.1
8h75ybw7vhmxkn
12 May 20
Current report (foreign)
12:04pm
424B5
26cpwcd8f2dnzz
12 May 20
Prospectus supplement for primary offering
12:02pm
6-K
EX-10.1
3su5la
11 May 20
VBL Therapeutics Announces $10.0 Million Registered Direct Offering
9:23am
6-K
EX-99.1
cfftwzbnazhe9qujcv5
11 May 20
VBL Therapeutics Announces $10.0 Million Registered Direct Offering
9:23am
424B5
voqgpi20 b2cn07
11 May 20
Prospectus supplement for primary offering
9:23am
6-K
EX-99.1
qlmmxm48i
26 Mar 20
VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study
8:08am
6-K
EX-99.1
udsrj4cd1um
19 Mar 20
Current report (foreign)
7:25am